Vitamin D Intervention in Infants - Pilot

NCT ID: NCT01275885

Last Updated: 2011-07-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

113 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of the present study are to evaluate the concentrations of vitamin D in the plasma and of calcium in the plasma and in the urine as well as to evaluate bone mineral density using peripheral quantitative computed tomography (pQCT), after supplementation of vitamin D with 30µg (1200 IU) and 40µg (1600 IU), in comparison with currently recommended supplementation of vitamin D with 10µg (400 IU). In this pilot study supplementation is given to infants from 2 weeks of age to 3 months of age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vitamin D deficiency is common around the world. In Finland vitamin D levels are low in all age groups. Especially infants are predisposed to vitamin D deficiency. Partly this is due to low exposure to sunlight but mainly it is due to low dietary intake of vitamin D. Vitamin D prophylaxis was introduced in Finland in the 1950´s to overcome rickets. However, the recommended dose has decreased from 50µg (2000 IU) in the 1960´s to 10µg (400 IU) from beginning of the 1990´s. The serum concentration of 25-hydroxyvitamin D (S-25OHD) is used as a marker of vitamin D status in the body. Although there is no consensus of optimal concentration of S-25OHD, it has been proposed that concentrations lower than 50 nmol/l indicate deficiency. According to recent findings on 25-OHD concentrations in Finnish children, currently recommended intake of vitamin D is inadequate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin D Supplementation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D3 10µg

Group Type ACTIVE_COMPARATOR

cholecalciferol (D3)

Intervention Type DIETARY_SUPPLEMENT

10µg (400 IU) orally daily for 10 weeks

Vitamin D3 30µg

Group Type ACTIVE_COMPARATOR

cholecalciferol (D3)

Intervention Type DIETARY_SUPPLEMENT

30µg (1200 IU) orally daily for 10 weeks

Vitamin D3 40µg

Group Type ACTIVE_COMPARATOR

cholecalciferol (D3)

Intervention Type DIETARY_SUPPLEMENT

40µg (1600 IU) orally daily for 10 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cholecalciferol (D3)

10µg (400 IU) orally daily for 10 weeks

Intervention Type DIETARY_SUPPLEMENT

cholecalciferol (D3)

30µg (1200 IU) orally daily for 10 weeks

Intervention Type DIETARY_SUPPLEMENT

cholecalciferol (D3)

40µg (1600 IU) orally daily for 10 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy Caucasian women with an uneventful pregnancy
* healthy infants born at term and appropriate for gestational age
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Helsinki

OTHER

Sponsor Role collaborator

Helsinki University Central Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Helsinki University Central Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sture Andersson, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Helsinki University Central Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital for Children and Adolescents, Helsinki University Central Hospital

Helsinki, , Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-015940-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

T1040D0038

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitamin D Supplementation in Breastfeeding Women
NCT01240265 COMPLETED PHASE2/PHASE3
A Study on Oral Vitamin D Megadoses
NCT01067898 COMPLETED PHASE4